NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, will be joining the National Organization for Rare Disorders (NORD) and other rare disease organizations around the world in observing World Rare Disease Day on February 28 to draw attention to rare diseases as an important global public health concern.
“As a company dedicated to the development of new biopharmaceuticals to treat rare gastrointestinal and endocrine disorders, we are pleased to show our continued support for Rare Disease Day,” said Francois Nader, M.D., president and chief executive officer of NPS Pharmaceuticals. “This annual observance celebrates the development of new treatments for rare diseases and highlights the continuing unmet needs of thousands of patients around the world with these conditions. We salute NORD, its members and its international affiliates for their commitment to finding new cures for these rare and often neglected diseases and disorders.”
“There are nearly 30 million Americans—and millions more around the world—affected by rare diseases,” said Peter L. Saltonstall, president and CEO of NORD. “Everyone knows someone with a rare disease. But, while many of these diseases are serious and lifelong, most have no treatment and many are not even being studied by researchers. This leaves patients and families without hope for a better future.”
A rare disease is one that affects fewer than 200,000 Americans. There are nearly 7,000 such diseases affecting nearly 30 million Americans.
No comments:
Post a Comment